Reimagining Access in Africa and Beyond
We’re working to build a self-sufficient vaccine ecosystem in Africa through local production, next-gen platforms, and smart delivery.
With LunaClinical, our U.S.-based clinical research network, we support global clinical trials and advance patient-centered research, strengthening health innovation and laying the foundation for equitable access worldwide.
Our Approach
Vaccine Manufacturing Hub
We are laying the groundwork for a state-of-the-art vaccine production facility in Nigeria to increase access, reduce import reliance, and secure future supply across Africa. The planned hub will focus on next-generation platforms including mRNA, saRNA, protein subunit, viral vector, and DNA-based vaccines, and enable local production of microneedle vaccine patches.
By investing in local production, we aim to strengthen self-reliance, lower costs, and improve response times during outbreaks.
Tech-Enabled Vaccine Vans & Clinics
We are advancing tech-enabled vans, mobile clinics, and pop-up units to expand immunization in underserved communities. These solutions reach remote areas, reducing barriers like distance, poor infrastructure, and limited healthcare access.
Working with our drone system, the vans will deliver on-the-spot immunization, bringing vaccines closer to families and communities.
Biometric ID for Vaccine Access
We are integrating biometric tools, such as fingerprint recognition and digital ID verification, into vaccine delivery programs to improve patient tracking, data accuracy, and continuity of care.
These tools help identify individuals without formal IDs, prevent missed doses, and ensure complete immunization, enabling more equitable and data-driven access, especially in regions with limited health records.
Drone Delivery & Smart Logistics
We are advancing drone-powered delivery to strengthen last-mile immunization, overcoming infrastructure gaps with autonomous flight paths and temperature-stable vaccines. This innovation reduces delivery times, eases cold chain barriers, and expands timely access to life-saving immunizations in hard-to-reach areas.
Designed to scale across vaccines such as measles, hepatitis B, DTP, HPV, TB, and malaria, this system represents a faster, more resilient model for equitable vaccine delivery.
Microneedle Vaccine Patches
We are advancing needle-free immunization through microneedle vaccine patches, which are painless, self-applied, and ideal for underserved communities. These patches require no cold storage or trained personnel, making them a natural fit with our drone and mobile clinic systems.
Currently focused on measles, we plan to expand into HPV, TB, and malaria, with long-term integration into national programs and local production.
Clinical Trials & Global Partnerships
With LunaClinical, our U.S.-based clinical research network, we support global clinical trials through regulatory coordination, site monitoring, and patient-centered research.
By partnering with health facilities, governments, and global health allies, we co-design and scale vaccine access solutions, powering innovations from microneedle patches and biometrics to mobile immunization and local manufacturing.
Every child deserves a shot at life. By fusing local production, last-mile delivery, and tech-driven care, LunaVax is proving what’s possible when we dare to be Lunacious.